BPCIA Patent Dance Timeline: What 54 Biosimilar Lawsuits Show
Congress wrote the BPCIA patent dance as a fixed sequence of 20-, 60-, 60-, 60-, 15- and 30-day steps. The
BPCIA Patent Dance Timeline: What 54 Biosimilar Lawsuits Show Read Post »
AI Drug Repurposing Scorecard: Two Approvals, Two Shutdowns, a $206,000 Quarter
A Lancet letter dated February 4, 2020 proposed baricitinib as a COVID-19 treatment. [1] Lilly announced FDA approval of that
AI Drug Repurposing Scorecard: Two Approvals, Two Shutdowns, a $206,000 Quarter Read Post »
AI Drug Questions Are Real-World Data Pharma Isn’t Reading
More than one in four of OpenAI’s 800 million regular ChatGPT users send a health prompt each week, according to
AI Drug Questions Are Real-World Data Pharma Isn’t Reading Read Post »
Grading the Lifecycle Playbook: What Keytruda, Stelara, and Eliquis Reveal About Patent-Cliff Strategy
Johnson & Johnson’s Stelara sales fell 59.7% year over year in the first quarter of 2026, to $656 million, after
Evergreening Fails When a Judge Reads Your Own Marketing Materials
Forest Laboratories and Actavis projected that only 30 percent of Namenda IR users would move to Namenda XR voluntarily before
Evergreening Fails When a Judge Reads Your Own Marketing Materials Read Post »
Method-of-Use Patents Only Work If Nobody Reads the Label Carefully
In March 2020, Hikma issued a press release that cited Vascepa sales of about $919 million for the 12 months
Method-of-Use Patents Only Work If Nobody Reads the Label Carefully Read Post »
Stop Defending Every Patent in the Portfolio: Triage Is a Strategy, Not a Concession
On December 20, 2024, the Federal Circuit affirmed an order that removed five Teva patents from the FDA Orange Book.
Stop Defending Every Patent in the Portfolio: Triage Is a Strategy, Not a Concession Read Post »
Your Device Patent Buys Four Years, Not Forty: What Happens When the Delivery Mechanism Becomes Prior Art
Device patents extended market protection for brand-name asthma and COPD inhalers by a median of 5.5 years beyond the last
Pay-for-Delay After Actavis: The Side Deal Is the Risk
In fiscal year 2021, drug companies filed 199 final patent settlements with the FTC. Twenty-two of them came with a
Pay-for-Delay After Actavis: The Side Deal Is the Risk Read Post »
